Info

TransMolecular, Inc. is a biotechnology company committed to discovering, developing, and commercializing novel, targeted therapies that promise to improve outcomes for gliomas, metastatic brain tumors, and other aggressive cancers with limited treatment options. Our mission: To extend survival and preserve quality of life for millions of cancer patients by providing therapies and delivery technologies that exclusively target malignant cells while avoiding interaction with normal, healthy cells. Company background - Founded in July 1996, TransMolecular is a privately held company backed by venture capital. Since its inception, the company has raised $42.8 million through three private placements from internationally recognized investment firms. The Company has built a strong management team with extensive experience in healthcare, pharmaceutical and biotechnology development, R&D, operations, business development, regulatory affairs, and finance. TransMolecular's corporate offices and R&D laboratories are in Cambridge, MA. The Company holds more than 35 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation for its technology.